Does tirzepatide protect the kidneys better than dulaglutide in type 2 diabetes?
Yes. In a randomized trial of 13,165 adults with type 2 diabetes and heart disease, tirzepatide cut major kidney events by 33 percent compared to dulaglutide. Kidney problems occurred in 4.9 percent of people on tirzepatide versus 6.1 percent on dulaglutide over the course of the study.
Both drugs are injectable medications taken once a week, and both are used to lower blood sugar in people with type 2 diabetes. Dulaglutide is a GLP-1 receptor agonist, which mimics one gut hormone that helps the body release insulin. Tirzepatide is newer and acts on two gut hormones at once, GIP and GLP-1. This study looked at how these two drugs compared for protecting the kidneys, which are often damaged by long-standing diabetes.
What the data show
The SURPASS-CVOT trial enrolled 13,165 adults from 30 countries who had type 2 diabetes plus atherosclerotic cardiovascular disease, meaning they already had narrowed or hardened arteries. Researchers randomly assigned them to receive either tirzepatide at up to 15 mg per week or dulaglutide at 1.5 mg per week, and then tracked them over time. Neither the patients nor the doctors knew which drug each person was getting, a design that keeps the results honest.
The headline finding was a hazard ratio of 0.67, with a 95 percent confidence interval of 0.52 to 0.87 and a P value of 0.002. In plain language, people on tirzepatide were about a third less likely to have a major kidney event than people on dulaglutide, and the result is statistically solid. The composite kidney outcome included four serious problems: new macroalbuminuria, which means a large amount of protein leaking into the urine, a drop in kidney filtering function of 50 percent or more, end-stage kidney disease requiring dialysis or transplant, and death from kidney causes.
Dr. Kumar’s Take
I find this trial genuinely useful because it is a head-to-head comparison rather than a comparison against placebo. Both drugs already work, so the real clinical question is which one to pick, and a 33 percent reduction in serious kidney events is a meaningful difference. The benefit also held up across different levels of baseline kidney risk, which suggests this is a real drug effect and not just an artifact of how the patients were grouped. I would still want to see longer follow-up and confirmation that the kidney advantage translates into fewer dialysis cases over a decade, but for now this gives clinicians one more reason to consider tirzepatide in patients with diabetes who also have heart disease and kidney concerns.
How the benefit played out across risk groups
One of the more interesting parts of this analysis is how the kidney advantage showed up differently depending on a patient’s starting CKD risk. In people at low to moderate risk for chronic kidney disease, the benefit was driven mostly by fewer cases of new-onset macroalbuminuria, meaning their kidneys were less likely to start leaking protein into the urine in the first place. In people who already had high CKD risk going in, the benefit came mostly from a slower drop in eGFR, the measure of how well the kidneys filter blood. So tirzepatide appeared to help earlier-stage patients avoid the first signs of kidney damage, while helping higher-risk patients hold onto the kidney function they still had.
Safety, limits, and caveats
The study was a pre-specified exploratory analysis, which is a step down from a confirmatory primary endpoint. That language matters because it tells you the researchers planned this kidney analysis ahead of time and the result is more reliable than a fishing expedition, but it is not the same as a kidney-focused trial designed to settle the question definitively. Everyone in this study also had established cardiovascular disease, so we cannot assume the same size of benefit in people with diabetes who do not already have heart problems. And the comparator was dulaglutide rather than placebo, so this tells us that tirzepatide is better than dulaglutide for kidneys, not that dulaglutide is bad. Both drugs likely protect kidneys compared to no treatment.
Practical Takeaways
- If you have type 2 diabetes plus heart disease and you are choosing between tirzepatide and dulaglutide, ask your doctor whether the kidney advantage shown in SURPASS-CVOT applies to your situation.
- Have your urine albumin and your eGFR checked at least once a year if you have type 2 diabetes, since rising protein in the urine is one of the earliest signs that diabetes is affecting your kidneys.
- Do not stop or switch a diabetes medication on your own based on a single study, especially since cost, insurance coverage, and side effect tolerance vary widely between these two drugs.
- Keep blood pressure, blood sugar, and weight in target ranges, because no medication can fully replace the kidney protection that comes from controlling those basics.
Related Studies and Research
- Does rosuvastatin prevent heart disease in healthy people with intermediate risk? A look at the HOPE-3 trial
- Does high LDL-C help elderly people live longer? A review of 19 studies
- Pantoprazole shows no increased kidney risk in major trial
- Single-dose psilocybin vs placebo: first double-blind depression trial
FAQs
Why does type 2 diabetes damage the kidneys in the first place?
High blood sugar over many years injures the tiny blood vessels inside the kidneys that filter waste out of your blood. The first sign of trouble is often small amounts of protein leaking into the urine, and over time the kidneys filter less efficiently, which shows up as a falling eGFR on a routine blood test. About one in three adults with type 2 diabetes will develop chronic kidney disease at some point, which is why annual urine and blood checks are part of standard diabetes care. Catching the problem early gives you the best chance to slow it down with medication, blood pressure control, and lifestyle changes.
Is the kidney benefit from tirzepatide just because it lowers blood sugar more?
That is a fair question and probably part of the story, but likely not the whole story. Tirzepatide does lower A1C and body weight more than dulaglutide in head-to-head studies, and both of those changes help the kidneys on their own. However, GLP-1 based drugs also appear to have direct effects on inflammation, blood pressure, and pressure inside the kidney filters that go beyond glucose control. The trial design here did not separate out these mechanisms, so it is reasonable to assume the kidney advantage is a combination of better glucose lowering, more weight loss, and some direct kidney effects from acting on both the GIP and GLP-1 pathways.
Should everyone with type 2 diabetes switch to tirzepatide for kidney protection?
No, this study does not support a blanket switch. The trial enrolled adults who already had atherosclerotic cardiovascular disease, so the strongest case for tirzepatide based on this data is in people who match that profile. Cost is also a real factor, since tirzepatide is expensive and insurance coverage varies, and some patients tolerate dulaglutide better in terms of nausea or other side effects. The right answer is an individual conversation with your doctor that weighs your kidney function, your heart history, your weight goals, your tolerance for side effects, and what your insurance will cover.
Bottom Line
In a large, well-run head-to-head trial, tirzepatide reduced major kidney events by 33 percent compared to dulaglutide in adults with type 2 diabetes and cardiovascular disease, with the benefit showing up across all levels of baseline kidney risk. This adds kidney protection to the growing list of reasons clinicians are reaching for tirzepatide in higher-risk diabetes patients, although cost, side effects, and individual circumstances still matter when choosing between the two drugs.
